Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

Abroad (travel likely)RecruitingPHASE2

Conditions

Amyloidosis · Transthyretin Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Oregon Health & Science University, Portland, Oregon, United States
Contact: Study coordinator (Ahmad Masri, MD) · masria@ohsu.edu
Contact: Principal Investigator (Ahmad Masri, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies

Abroad (travel likely)RecruitingPHASE2

Chandler, United States · Scottsdale, United States

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis · Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nashville, United States · Dallas, United States

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis Polyneuropathy · Transthyrexin Amyloidosis Cardiomyopathy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China · Changsha, China

The Eplontersen Pregnancy and Lactation Outcomes Study

Transthyretin Amyloidosis

Abroad (travel likely)Recruiting

Frankfurt, Germany